Cardiovascular medicine in the era of COVID-19 pandemics.
作者信息
Ren Jun
机构信息
Department of Cardiology, Shanghai Institute for Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 200032, China; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
出版信息
Cardiol Plus. 2021 Oct 1;6(4):199-201. doi: 10.4103/2470-7511.334404. Epub 2021 Dec 30.
Abstract
摘要
相似文献
1
Cardiovascular medicine in the era of COVID-19 pandemics.新冠疫情时代的心血管医学
Cardiol Plus. 2021 Oct 1;6(4):199-201. doi: 10.4103/2470-7511.334404. Epub 2021 Dec 30.
2
Patient Use and Clinical Practice Patterns of Remote Cardiology Clinic Visits in the Era of COVID-19.新冠疫情时期远程心脏病学诊所就诊的患者使用情况和临床实践模式。
JAMA Netw Open. 2021 Apr 1;4(4):e214157. doi: 10.1001/jamanetworkopen.2021.4157.
3
Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era.心血管内科医生和医院内科医生在 COVID-19 时代的考虑因素。
Am J Med. 2020 Nov;133(11):1254-1261. doi: 10.1016/j.amjmed.2020.06.005. Epub 2020 Jul 10.
4
Cardiovascular Disease in the Post-COVID-19 Era - the Impending Tsunami?新冠疫情后时代的心血管疾病——即将到来的海啸？
Heart Lung Circ. 2020 Jun;29(6):809-811. doi: 10.1016/j.hlc.2020.04.004. Epub 2020 Apr 16.
5
Behavioral Medicine in the COVID-19 Era: Dawn of the Golden Age.行为医学在新冠时代：黄金时代的黎明。
Ann Behav Med. 2020 Aug 8;54(8):541-543. doi: 10.1093/abm/kaaa057.
6
Burden of COVID-19 pandemic on tuberculosis hospitalisation patterns at a tertiary care hospital in Rajasthan, India: a retrospective analysis.印度拉贾斯坦邦一家三级护理医院中 COVID-19 大流行对结核病住院模式的影响：一项回顾性分析
BMJ Open. 2024 May 3;14(5):e080623. doi: 10.1136/bmjopen-2023-080623.
7
Designing Futuristic Telemedicine Using Artificial Intelligence and Robotics in the COVID-19 Era.在新冠疫情时代利用人工智能和机器人技术设计未来远程医疗
Front Public Health. 2020 Nov 2;8:556789. doi: 10.3389/fpubh.2020.556789. eCollection 2020.
8
Revascularization prevents amputation among patients with diabetic foot during the COVID-19 era.在新冠疫情期间，血运重建可预防糖尿病足患者截肢。
Vascular. 2023 Aug;31(4):729-736. doi: 10.1177/17085381221079108. Epub 2022 Mar 21.
9
Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: Gender makes a difference.新冠疫情时代的抑郁大流行与心血管风险和长新冠综合征：性别差异。
Trends Cardiovasc Med. 2022 Jan;32(1):12-17. doi: 10.1016/j.tcm.2021.09.009. Epub 2021 Oct 5.
10
Collaboration during Crisis: A Novel Point-of-Care Ultrasound Alliance among Emergency Medicine, Internal Medicine, and Cardiology in the COVID-19 Era.危机期间的合作：COVID-19 时代急诊医学、内科和心脏病学之间新型的床旁超声联盟
J Am Soc Echocardiogr. 2021 Mar;34(3):325-326. doi: 10.1016/j.echo.2020.11.019. Epub 2020 Dec 3.
引用本文的文献
1
Injury mechanism of COVID-19-induced cardiac complications.新型冠状病毒肺炎所致心脏并发症的损伤机制
Cardiol Plus. 2023 Jul-Sep;8(3):159-166. doi: 10.1097/CP9.0000000000000055. Epub 2023 Jun 23.
本文引用的文献
1
COVID-19-induced cardiovascular damage differs from other prevalent viruses.新冠病毒（COVID-19）引发的心血管损伤不同于其他常见病毒。
Cardiol Plus. 2021 Oct 1;6(4):231-245. doi: 10.4103/2470-7511.334401. Epub 2021 Dec 30.
2
Challenges in management of ST elevation myocardial infarction during COVID-19 pandemic.2019冠状病毒病大流行期间ST段抬高型心肌梗死的管理挑战
Cardiol Plus. 2021 Oct 1;6(4):218-230. doi: 10.4103/2470-7511.334400. Epub 2021 Dec 30.
3
Management of hypertension in patients with COVID-19: Implication of angiotensin-converting enzyme 2.2019冠状病毒病患者的高血压管理：血管紧张素转换酶2的影响
Cardiol Plus. 2021 Oct 1;6(4):210-217. doi: 10.4103/2470-7511.334397. Epub 2021 Dec 30.
4
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.ESC 指导意见：COVID-19 大流行期间心血管疾病的诊断和管理：第 2 部分——治疗途径、治疗和随访。
Cardiovasc Res. 2022 Jun 22;118(7):1618-1666. doi: 10.1093/cvr/cvab343.
5
COVID-19: The Impact on Cardiovascular System.新型冠状病毒肺炎：对心血管系统的影响
Biomedicines. 2021 Nov 15;9(11):1691. doi: 10.3390/biomedicines9111691.
6
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.欧洲心脏病学会在 COVID-19 大流行期间心血管疾病的诊断和管理指南：第 1 部分-流行病学、病理生理学和诊断。
Eur Heart J. 2022 Mar 14;43(11):1033-1058. doi: 10.1093/eurheartj/ehab696.
7
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications.肥胖性心肌病：证据、机制与治疗意义。
Physiol Rev. 2021 Oct 1;101(4):1745-1807. doi: 10.1152/physrev.00030.2020. Epub 2021 May 5.
8
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.SARS-CoV-2 与心血管并发症：从分子机制到药物治疗管理。
Biochem Pharmacol. 2020 Aug;178:114114. doi: 10.1016/j.bcp.2020.114114. Epub 2020 Jun 21.
9
Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges.社论：缺血再灌注损伤与心脏代谢疾病管理中的新治疗方法：机遇与挑战
Curr Drug Targets. 2017;18(15):1687-1688. doi: 10.2174/138945011815171019092703.
10
Bridging the Gap, Facing the Challenge-the 26(th) Great Wall International Congress of Cardiology (GW-ICC).弥合差距，直面挑战——第26届长城国际心脏病学会议（GW-ICC）
Cardiovasc Diagn Ther. 2016 Feb;6(1):97-100. doi: 10.3978/j.issn.2223-3652.2016.01.01.
Zotero 插件